Clinical trial
Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure
NCT00403910 is registered in ClinicalTrials.gov with Heart Care Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure
- Lead sponsor
- Heart Care Foundation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2002
- Completion date
- July 31, 2006
- Enrollment
- 500
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.